+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06309485

Open-Label Study of WGI-0301 with Sorafenib Compared to Sorafenib Alone in Adults with Advanced Hepatocellular Carcinoma

Led by Zhejiang Haichang Biotech Co., Ltd. · Updated on 2026-09-11

60

Participants Needed

9

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the maximum tolerated dose MTD of WGI-0301 combined with Sorafenib for adults with advanced hepatocellular carcinoma HCC who have previously received PD-1 or PD-L1 immune checkpoint inhibitors. This phase 2 study aims to assess the safety and effectiveness of this combination treatment compared to Sorafenib alone in patients with advanced, unresectable HCC. The study has two stages Stage 1 involves dose escalation to find the MTD or recommended Phase 2 dose RP2D of WGI-0301 combined with Sorafenib. Stage 2 expands to compare two dose levels of WGI-0301 plus standard dose Sorafenib against standard dose Sorafenib alone. WGI-0301 is given as a weekly intravenous infusion, while Sorafenib is taken orally twice daily continuously. Participants will undergo screening for eligibility, then receive assigned treatments based on randomization. Researchers will monitor tumor response using RECIST 1.1 criteria and evaluate safety, tolerability, and anti-tumor activity over about two years. Assessments include imaging to measure tumor lesions, laboratory tests, and clinical evaluations during treatment and follow-up periods to track outcomes and side effects.

CONDITIONS

Brief Title

Phase 2 Study of WGI-0301 for Advanced HCC

Research Team

A

Angela Men, MD., Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here